A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma

The chimeric monoclonal antibody cG250 recognises the G250/CAIX/MN antigen found on 95% of clear cell renal cell carcinomas (RCCs). We performed a phase I clinical trial to evaluate the safety, blood pharmacokinetics (PK), and biodistribution of repeated doses of cG250. The primary endpoint was toxi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Davis, Ian D., Wiseman, Gregory A., Lee, Fook-Thean, Gansen, Denise N., Hopkins, Wendie, Papenfuss, Anthony T., Liu, Zhanqi, Moynihan, Timothy J., Croghan, Gary A., Adjei, Alex A., Hoffman, Eric W., Ingle, James N., Old, Lloyd J., Scott, Andrew M.
Formato: Artigo
Idioma:Inglês
Publicado em: Academy of Cancer Immunology 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935755/
https://ncbi.nlm.nih.gov/pubmed/17705349
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados